Tam M. Nguyen

Array ( [id] => 19903038 [patent_doc_number] => 12280022 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Method of treating major depressive disorder [patent_app_type] => utility [patent_app_number] => 18/504388 [patent_app_country] => US [patent_app_date] => 2023-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8025 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19012956 [patent_doc_number] => 11919871 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-05 [patent_title] => 3-(3-chlorophenyl)-5-((2-isopropyl-5- methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/386565 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4471 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265276 [patent_doc_number] => 20240208975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => MACROCYCLIC HETEROCYCLES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/497515 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19441178 [patent_doc_number] => 12091418 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Anti-tumor compound and preparation method and use thereof [patent_app_type] => utility [patent_app_number] => 18/495455 [patent_app_country] => US [patent_app_date] => 2023-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 88682 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18495455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19889069 [patent_doc_number] => 20250114381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-10 [patent_title] => Cannabinoid Composition and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/376679 [patent_app_country] => US [patent_app_date] => 2023-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18376679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20592392 [patent_doc_number] => 12576088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B [patent_app_type] => utility [patent_app_number] => 18/468453 [patent_app_country] => US [patent_app_date] => 2023-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 8 [patent_no_of_words] => 5767 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18468453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599515 [patent_doc_number] => 20240390395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => APPLICATION OF ION CHANNEL BLOCKER IN TREATMENT AND/OR PREVENTION OF HEPATIC FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/467687 [patent_app_country] => US [patent_app_date] => 2023-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18467687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842586 [patent_doc_number] => 20230404990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => NEUROPROTECTIVE CB2 RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 18/461595 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19074755 [patent_doc_number] => 11944094 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-04-02 [patent_title] => Seed germination activator for control of broomrape [patent_app_type] => utility [patent_app_number] => 18/235026 [patent_app_country] => US [patent_app_date] => 2023-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 2499 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18235026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18893712 [patent_doc_number] => 20240009197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => TREATMENT OF INDOLENT OR AGGRESSIVE B-CELL LYMPHOMAS USING A COMBINATION COMPRISING BTK INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/450256 [patent_app_country] => US [patent_app_date] => 2023-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 485 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18450256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20262922 [patent_doc_number] => 12433890 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Method of treating SCLC and managing neutropenia [patent_app_type] => utility [patent_app_number] => 18/448124 [patent_app_country] => US [patent_app_date] => 2023-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 14 [patent_no_of_words] => 45969 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18815947 [patent_doc_number] => 20230390286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => METHOD OF TREATING SCLC AND MANAGING THROMBOCYTOPENIA [patent_app_type] => utility [patent_app_number] => 18/448145 [patent_app_country] => US [patent_app_date] => 2023-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921430 [patent_doc_number] => 20240024434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450 [patent_app_type] => utility [patent_app_number] => 18/230039 [patent_app_country] => US [patent_app_date] => 2023-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18230039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18970324 [patent_doc_number] => 20240050416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => Stable Pharmaceutical Compositions of Apixaban [patent_app_type] => utility [patent_app_number] => 18/357295 [patent_app_country] => US [patent_app_date] => 2023-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18357295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18737821 [patent_doc_number] => 20230346719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => MULTIPLE MYELOMA TREATMENT [patent_app_type] => utility [patent_app_number] => 18/350914 [patent_app_country] => US [patent_app_date] => 2023-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18350914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20270727 [patent_doc_number] => 12440491 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => KRAS G12C inhibitors and methods of using the same [patent_app_type] => utility [patent_app_number] => 18/213464 [patent_app_country] => US [patent_app_date] => 2023-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 176654 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 398 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18213464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725749 [patent_doc_number] => 20230339952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => MACROCYCLIC HETEROCYCLES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/328109 [patent_app_country] => US [patent_app_date] => 2023-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 1030 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18328109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18690873 [patent_doc_number] => 20230321035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER [patent_app_type] => utility [patent_app_number] => 18/325883 [patent_app_country] => US [patent_app_date] => 2023-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18325883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806857 [patent_doc_number] => 20230381190 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => Methods and Treatment for Complex Lymphatic Malformations [patent_app_type] => utility [patent_app_number] => 18/323488 [patent_app_country] => US [patent_app_date] => 2023-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18323488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769350 [patent_doc_number] => 20230364109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => GANAXOLONE FOR USE IN TREATMENT OF SUPER REFRACTORY STATUS EPILEPTICUS [patent_app_type] => utility [patent_app_number] => 18/321374 [patent_app_country] => US [patent_app_date] => 2023-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18321374 [rel_patent_id] =>[rel_patent_doc_number] =>)